Child and Adolescent Psychiatry and Mental Health
September 14, 2023
Xiaofeng Lan, Chengyu Wang, Fan Zhang et al.
22 citations
BACKGROUND: Ketamine and its enantiomer have rapid and robust effects on depressive symptom and suicidal ideation. Little is known about their cognitive effects in adolescents. We aimed to evaluate the short-term effect of esketamine on cognition in adolescents with major depressive disorder (MDD) and suicidal ideation. METHOD: In this randomized-controlled trial, 51 participants aged 13-18...
Acta Psychiatrica Scandinavica
September 8, 2023
Giacomo D’andrea, Mauro Pettorruso, T. Rhee et al.
8 citations
Depressive disorders represent a significant economic and health burden globally. This is particularly evident in treatment-resistant depression (TRD), commonly defined as the absence of a satisfactory response to at least two different antidepressant trials (as defined by the U.S. Food and Drug Administration/FDA and European Medicine Agencies/EMA). The foregoing TRD cases frequently manifest...
Clinical Psychopharmacology and Neuroscience
September 6, 2023
Julia Vendrell-Serres, Oscar Soto-Angona, Amanda Rodríguez‐Urrutia et al.
8 citations
Objective: : Treatment Resistant Depression (TRD) is commonly defined as the lack of response to two or more anti-depressants with different mechanisms of action. Up to 30% of patients diagnosed with major depressive disorder might be considered to present TRD. The objective of this study was to assess the effectiveness and tolerability of esketamine in patients diagnosed with TRD, who were...
The American Journal of Drug and Alcohol Abuse
September 3, 2023
Joseph J Palamar
29 citations
A drug concoction called tusi has emerged in Latin America and in Europe and is now beginning to acquire popularity in the United States. "Tusi" is a phonetic translation of "2C," a series of psychedelic phenethylamines. The concoction is also sometimes referred to as "pink cocaine" as it typically comes in the form of pink powder. However, despite its name, the concoction rarely contains 2C...
The Brown University Psychopharmacology Update
September 1, 2023
Interim results from a Phase 3 study of esketamine nasal spray in patients with treatment‐resistant depression showed no emerging safety concerns and sustained improvement in depressive symptoms. Nearly half of study participants met criteria for remission at the end of the study's optimization/maintenance phase, the investigators reported. Study results were published online May 12, 2023, in...
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
September 2023
Chan Li, Jiping Zhang, Hanhe Liu et al.
Depression is a multifactorial syndrome with a variety of underlying pathological mechanisms. While ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, exhibits a rapid antidepressant action in the central never system (CNS), the potential addiction and psychotomimetic adverse effects of ketamine limit its chronic use in clinical practice. Therefore, it is necessary to discover an...
Journal of Psychoactive Drugs
September 1, 2023
V. Tsang, Dragos C Razagan, P. Kryskow et al.
10 citations
ABSTRACT The prevalence of depression, anxiety, and post-traumatic stress disorder (PTSD) has increased among healthcare providers, while the effectiveness of conventional treatments remains limited. Ketamine-assisted therapy offers a promising alternative; however, few have integrated ketamine with a group-based therapeutic modality. We report a retrospective, secondary analysis of a 12-week...
The Brown University Psychopharmacology Update
September 1, 2023
A large‐scale open‐label trial conducted at electroconvulsive therapy (ECT) clinics has found that twice‐weekly dosing of ketamine was noninferior to three sessions a week of ECT in patients with treatment‐resistant major depression. Relapse rates during a 6‐month follow‐up period after the initial 3‐week treatment period were higher among patients receiving ECT than patients receiving...
International Clinical Psychopharmacology
September 1, 2023
Nicolas Garel, Michka Nazon, Kamran Naghi et al.
7 citations
Medical Aid in Dying (MAiD) is the act of a healthcare provider ending a patient's life, at their request, due to unbearable suffering from a grievous and incurable disease. Access to MAiD has expanded in the last decade and, more recently, it has been made available for psychiatric illnesses in a few countries. Recent studies have found that such psychiatric requests are rapidly increasing and...
Pharmacology, Biochemistry, and Behavior
September 1, 2023
Yixue Qin, Haoxuan Li, Yuqi Zhang et al.
6 citations
Ketamine has been increasingly used as a rapid-onset antidepressant in specific clinical settings. However, as a psychedelic reagent, the potential of physical and psychological dependence limits its clinical use. Here, we added retigabine, a KCNQ channel opener, as an adjunctive treatment to observe its effect on ketamine's antidepressant property in a forced swim test in both male and female...
Research Square
August 28, 2023
preprint
Abstract: After resolution of primary infection, patients are susceptible to more severe secondary infection with unclear underlying mechanisms.To investigate whether esketamine treatment immediately after primary LPS exposure could alleviate second-infection-induced cognitive impairment. In this study, mice were injected intraperitoneally (i.p.) with lipopolysaccharides (LPS; 5 mg/kg) 10 days...
Journal of Exploratory Research in Pharmacology
August 28, 2023
Ryan Dao, Amit Aggarwal
2 citations
Major depressive disorder (MDD) continues to be a prevalent disease worldwide. While selective serotonin reuptake inhibitors and other medications continue to be prescribed, further research has been conducted toward other treatment modalities. Within the past decade, ketamine, an N-methyl-d-aspartate receptor antagonist, has been extensively studied as a new treatment for MDD. Recent studies...
bioRxiv (Cold Spring Harbor Laboratory)
August 28, 2023
Nicholas Kolbman, Tiecheng Liu, Peter R. Guzzo et al.
preprint
Abstract There is a renewed interest in the therapeutic potential of psychedelics, including psilocybin, in treating mental health disorders. However, there are no data on the efficacy of psilocybin in alleviating chronic pain. In this study, we investigated the effect of psilocybin on mechanical hypersensitivity and thermal hyperalgesia in a rat model of formalin-induced chronic pain. Adult...
International Journal of Basic & Clinical Pharmacology
August 25, 2023
Veena Verma, Pankaj P. Sanone, Ashish K. Mehta et al.
Background: The present study was designed to investigate the effect of citalopram, ketamine, glycine and their combinations on animal models of depression. Methods: Swiss Albino male mice were subjected to chronic mild stress for 6 weeks for inducing depression, and randomly divided into different groups: citalopram (5 and 10 mg/kg), ketamine (17.5 and 35 mg/kg), glycine (50 and 100 mg/kg),...
New Zealand Medical Journal
August 25, 2023
Roger Mulder, Ben Beaglehole, James Foulds
The New Zealand Medical Journal (NZMJ) is the principal scientific journal for the medical profession in New Zealand. The Journal has become a fundamental resource for providing research and written pieces from the health and medical industry.
Psychiatry Research Case Reports
August 20, 2023
Brian S. Barnett, Amit Anand
Though usually mild, neuropsychiatric side effects of intravenous ketamine for depression occasionally result in treatment discontinuation. Two small clinical trials of healthy subjects have indicated that lamotrigine pre-treatment may attenuate these side effects, though two other trials, one in patients with unipolar depression and one in healthy male volunteers, did not support these...
Trials
August 19, 2023
Kaili Yu, Zhenguo Song, Bowen Zhang et al.
Pancreatoduodenectomy (PD) is traumatic, difficult to perform, and has a high incidence of postoperative complications and perioperative mortality. Postoperative complications and pain occur frequently and seriously affect the psychological status of patients. Esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has analgesic and antidepressant effects. In this study, we aim to...
Depression and Anxiety
August 19, 2023
Anna J. Harvey, Stevan Nikolin, Nicholas Chand et al.
4 citations
Ketamine has recently emerged as a highly effective new treatment for people with treatment-resistant depression with rapid antidepressant effects. However, these effects are often short lasting, and the potential cognitive mechanisms underlying the therapeutic effects, such as effects on emotional processing bias, remain poorly understood. In the present study, we explored potential changes in...
American Journal of Psychiatry and Neuroscience
August 17, 2023
Marcus C. Rosenhagen, Julien Elowe, Alberto Forte et al.
Ketamine, initially developed as a safer alternative to phencyclidine, has emerged as a groundbreaking treatment in psychiatric practice. It gained popularity after its approval by the FDA in 1970 for its analgesic properties and ability to induce altered consciousness while maintaining vital functions. In the 1990s, researchers discovered its rapid and potent antidepressant effects, especially...
Scientific Reports
August 16, 2023
Zümrüt Duygu Sen, Tara Chand, Lena Vera Danyeli et al.
Ketamine is a rapid-acting antidepressant that also influences neural reactivity to affective stimuli. However, the effect of ketamine on behavioral affective reactivity is yet to be elucidated. The affect-modulated startle reflex paradigm (AMSR) allows examining the valence-specific aspects of behavioral affective reactivity. We hypothesized that ketamine alters the modulation of the startle...